NCT00818649 arm group d6ab6152e90b0c0f5095d9ec4457b372 [clinicaltrials_resource:NCT00818649/arm-group/d6ab6152e90b0c0f5095d9ec4457b372]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00818649 arm group d6ab6152e90b0c0f5095d9ec4457b372 [clinicaltrials_resource:NCT00818649/arm-group/d6ab6152e90b0c0f5095d9ec4457b372]
Bio2RDF identifier
NCT00818649/arm-group/d6ab6152e90b0c0f5095d9ec4457b372
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... ab6152e90b0c0f5095d9ec4457b372
description [clinicaltrials_vocabulary:description]
This is a phase II two stage s ...... a total of 3 treatment cycles.
identifier
clinicaltrials_resource:NCT00818649/arm-group/d6ab6152e90b0c0f5095d9ec4457b372
title
NCT00818649 arm group d6ab6152e90b0c0f5095d9ec4457b372
@en
type
label
NCT00818649 arm group d6ab6152 ...... b6152e90b0c0f5095d9ec4457b372]
@en